Northeastern clinicians say GLP-1 weight loss culture may raise eating disorder risk
A new expert commentary says the cultural buzz around GLP-1 weight loss may make disordered eating more likely for some people, though how often that happens is still unknown.
The return of visible weight-loss talk to mainstream American culture — driven in part by GLP-1 drugs such as Ozempic, Wegovy and Mounjaro — may be raising the risk of disordered eating, two clinicians at Northeastern University argue in commentary published Aug. 19, 2026 [1]. The piece is expert opinion and draws on published statistics and clinical experience; it presents no new research data on GLP-1 users [1].
Ashleigh Shields, a professor in Northeastern's Bouvé College of Health Sciences, said every generation has had its "magic diet pills," and that many of those products were later banned or restricted by the FDA [1]. She described GLP-1s as different — mainstream, legitimate, and a benefit to people who need them — but questioned what happens around the drugs. "People are rushing to do these things without really thinking about or understanding the consequences," she said [1].
The article cites the National Eating Disorders Association (NEDA), which reports that 9 percent of the U.S. population has faced an eating disorder at some point in life, or nearly 31 million Americans, and that one person dies as a direct consequence of an eating disorder every 52 minutes [1]. NEDA states that the full extent of the effect of drugs like Ozempic on eating disorders is still unknown, and urges caution with GLP-1s because of potential risks to those groups [1]. The commentary does not put a number on how many GLP-1 users develop disordered eating, and no such figure has been reported [1].
Shields groups the full spectrum of restrictive behaviors under the term "DEEDs," combining disordered eating and eating disorders [1]. She described her own history: cutting food into tiny pieces, treating grapes as a "safe" food, imagining pasta as "worms" to blunt her appetite, filling gaps with gum and mints, and by college running roughly 12 to 18 miles a day while training for marathons [1].
Psychologist Alexis Conason, author of "The Diet-Free Revolution," told Northeastern Global News that before the GLP-1 era there was "more of a sense of rejecting the diet mentality," and that the drugs have flipped the narrative so that being thin now looks like a matter of personal responsibility [1]. Shields said beauty standards follow weight loss back to center stage: "Unfortunately right now heroin chic is back," she said, describing the Y2K-era thin look returning as the "Ozempic body" [1].
The article notes that singer Meghan Trainor, whose 2014 hit "All About That Bass" rejected size-two ideals, has said she lost 60 pounds using Mounjaro, according to her Instagram posts and interviews, and that Serena Williams, Oprah Winfrey, Andy Cohen and Whoopi Goldberg have also publicly disclosed GLP-1 use [1].
Shields said weight loss can take on a life of its own: "Once you get to that number, it's never enough" [1]. She described compliments from family and friends as fuel, and said that because GLP-1 tolerance builds over time, people often regain what they lost and then some — a point she called vulnerable for disordered eating. "It's a slippery slope," she said [1].
Why it matters for patients
The concern here is not that GLP-1s cause eating disorders in everyone. NEDA's position, as described in the article, is that the scale of the effect is unknown and that caution is warranted for people at risk [1]. What the commentary adds is a cultural argument: that heavier weight-loss messaging, combined with weight that now seems controllable, can make restriction feel like discipline rather than a problem [1].
For people already taking these drugs, the article describes two pressure points. One is the speed and apparent ease of the loss, which Shields said can intensify a drive to keep going [1]. The other is regain after tolerance builds, which she described as a moment when people become more susceptible to disordered eating [1]. The commentary does not describe screening protocols, treatment pathways or how patients should raise these concerns with a prescriber, and those specifics are not included [1].
What happens next
No new study, regulatory action or guideline is attached to the commentary, and no dated milestone is named in it [1]. NEDA's call for caution with GLP-1s stands as the article's only stated position from a patient organization [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.